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Abstract
Over the last years, evidence has accumulated suggesting that by systematically reducing the amount of dietary
carbohydrates (CHOs) one could suppress, or at least delay, the emergence of cancer, and that proliferation of
already existing tumor cells could be slowed down. This hypothesis is supported by the association between
modern chronic diseases like the metabolic syndrome and the risk of developing or dying from cancer. CHOs or
glucose, to which more complex carbohydrates are ultimately digested, can have direct and indirect effects on
tumor cell proliferation: first, contrary to normal cells, most malignant cells depend on steady glucose availability in
the blood for their energy and biomass generating demands and are not able to metabolize significant amounts
of fatty acids or ketone bodies due to mitochondrial dysfunction. Second, high insulin and insulin-like growth
factor (IGF)-1 levels resulting from chronic ingestion of CHO-rich Western diet meals, can directly promote tumor
cell proliferation via the insulin/IGF1 signaling pathway. Third, ketone bodies that are elevated when insulin and
blood glucose levels are low, have been found to negatively affect proliferation of different malignant cells in vitro
or not to be usable by tumor cells for metabolic demands, and a multitude of mouse models have shown anti-
tumorigenic properties of very low CHO ketogenic diets. In addition, many cancer patients exhibit an altered
glucose metabolism characterized by insulin resistance and may profit from an increased protein and fat intake.
In this review, we address the possible beneficial effects of low CHO diets on cancer prevention and treatment.
Emphasis will be placed on the role of insulin and IGF1 signaling in tumorigenesis as well as altered dietary needs
of cancer patients.
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Introduction
When defining the factors of a healthy lifestyle that aims
at preventing a disease like cancer, a logical approach is
to compare individuals that get the disease with those
that don’t. Cancer, which might be considered a disease
of civilization, has consistently been reported to be very
rare among uncivilized hunter-gatherer societies [1-4].
This observation makes sense from an evolutionary per-
spective from which it is reasonable to assume that the
lifestyle factors that protect our genome against tumori-
genesis have been selected for early in the history of the
genus homo when humans lived as hunter-gatherers [5].
In particular, the time since the neolithic revolution,
which meant the transition from foraging and nomad-
ism to agriculture and settlement, spans a fraction less
than 1% of human history. Thus, the switch from the
“caveman’s diet” consisting of fat, meat and only occa-
sionally roots, berries and other sources of carbohydrate
(CHO) to a nutrition dominated by easily digestible
CHOs derived mainly from grains as staple food would
have occurred too recently to induce major adoptions in
our genes encoding the metabolic pathways. This is
even more the case for the changes that occurred over
the past 100 years, in particular the switch from labor in
the field to a sedentary lifestyle and an increase in the
consumption of easily digestible CHOs with high glyce-
mic indices (GIs), leading to diseases of civilization that
are strongly associated with the so-called Western way
of life [6]. Despite a large heterogeneity in regional
occupation, modern hunter-gatherers share certain
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lifestyle factors that are not frequently met in Wester-
nized societies, including regular physical activity, sun
exposure, sufficient sleep, low chronic stress and the
lack of foods that would also not have been available to
our pre-neolithic ancestors. While there is already com-
pelling evidence for the beneficial roles of regular physi-
cal activity and sufficient vitamin D in the prevention
and treatment of cancer, the influence of the altered
nutritional patterns in the Western diet is less clearly
defined.
Modern hunter-gatherers’ diet
Data from 229 hunter-gatherer societies included in the
revised Ethnographic Atlas indicate that hunter-gatherer
diets differ from typical Western ones in basically two
aspects: first, a strong reliance on animal foods (45-65%
of energy or E%) and second, the consumption of low-
GI plant foods such as vegetables, fruits, seeds and nuts
[7]. This is consistent with stable isotope studies of
human fossils [8,9]. As a consequence, the amount and
type of carbohydrates in the typical western diet differ
markedly from the ones that our genes adapted to. In
particular, Cordain and colleagues estimated that mod-
ern hunter-gatherers derived about 22-40 E% from
CHOs and 19-30 E% from protein, which is lower and
higher, respectively, than recommended by Western
food agencies. Recently, Ströhle & Hahn confirmed that
the energy derived from CHOs - despite being depen-
dent upon geographic latitude and ecological environ-
ment - in modern hunter-gatherers is markedly lower
than in Westernized societies [10]. High CHO intake, in
particular in the form of sugar and other high GI foods,
has been linked to modern diseases like metabolic syn-
drome [11], Alzheimer’s disease [12,13], cataract and
macula degeneration [14-16] and gout [17]. Intriguingly,
with the possible exception of Alzheimer’s disease [18],
the occurrence and prognosis of cancer seems positively
associated with both the prevalence of these diseases
[19-28] and the GI and glycemic load (GL) of the diet
[29-32]; this implies a possible role of high CHO intake
in cancer as well.
In this review, we are going to present some argu-
ments that support the hypothesis that lowering the
amount of CHOs in the diet can have direct beneficial
effects on the prevention and treatment of malignant
diseases. The main focus will be on very low CHO,
ketogenic diets as an effective supportive therapy option
for cancer patients.
Tumor cell metabolism - it’s all about glucose
That there exists an intimate connection between CHOs
and cancer has been known since the seminal studies
performed by different physiologists in the 1920s. Treat-
ing diabetic patients, A. Braunstein observed in 1921
that in those who developed cancer, glucose secretion in
the urine disappeared. Further, culturing tissue of
benign and malign origin in glucose-containing solu-
tions, he quantified the much higher consumption by
cancer tissue compared to muscle and liver [33]. One
year later, R. Bierich described the remarkable accumu-
lation of lactate in the micromilieu of tumor tissues [34]
and demonstrated lactate to be essential for invasion of
melanoma cells into the surrounding tissue [35]. The
most accurate and well known experiments were pub-
lished by Otto Warburg and colleagues from 1923 on
[36-38]. Warburg observed that tumor tissue ex vivo
would convert high amounts of glucose to lactate even
in the presence of oxygen (aerobic glycolysis), a meta-
bolic phenotype now referred to as the Warburg effect.
This meant a sharp contrast to normal tissue which was
known to exhibit the Pasteur effect, i.e., a decrease of
glucose uptake and inhibition of lactate production
under aerobic conditions. Today, the Warburg effect is
an established hallmark of cancer, i.e., a pathological
capability common to most, if not all, cancer cells [39].
At first sight, the reason why many cancers should run
preferentially on glucose to produce energy seems coun-
ter-intuitive: basic biochemistry textbooks tell us that
glycolysis partially oxidizes the carbon skeleton of one
mole of glucose to two moles of pyruvate, yielding two
moles of ATP and NADH. In normal cells under nor-
moxic conditions, pyruvate is oxidized in the mitochon-
dria by the enzyme pyruvate dehydrogenase, creating
acetyl-CoA which is further utilized in the tricarboxylic
acid cycle (TCA or Krebs cycle) to yield a total of 32+
moles of ATP. Thus, the oxidation of pyruvate in the
mitochondria supplies 30+ additional moles of ATP
compared to its reduction to lactate via lactate dehydro-
genase A (LDHA), which happens in case of insufficient
oxygen levels or - in case of cancer cells - due to the
Warburg effect.
Possible causes for the “Warburg effect”
Over the past years, however, it has become increasingly
clear that malignant cells compensate for this energy
deficit by up-regulating the expression of key glycolytic
enzymes as well as the glucose transporters GLUT1 and
GLUT3, which have a high affinity for glucose and
ensure high glycolytic flux even for low extracellular
glucose concentrations. This characteristic is the basis
for the wide-spread use of the functional imaging mod-
ality positron emission tomography (PET) with the glu-
cose-analogue tracer 18F-fluoro-2-deoxyD-glucose (FDG)
(Figure 1). There are mainly four possible drivers dis-
cussed in the literature that cause the metabolic switch
from oxidative phosphorylation to aerobic glycolysis in
cancer cells. The first one is mitochondrial damage or
dysfunction [40], which was already proposed by
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Warburg himself as the cause for tumorigenesis [41].
Somatic mutations in mitochondrial DNA (mtDNA) and
certain OXPHOS genes can lead to increased produc-
tion of reactive oxygen species (ROS) and accumulation
of TCA cycle intermediates (succinate and fumarate)
that trigger the stabilization of hypoxia inducible factor
(HIF)-1a, inactivation of tumor suppressors including
p53 and PTEN and upregulation of several oncogenes of
the phosphoinositide 3-kinase (PI3K)/Akt/mammalian
target of rapamycin (mTOR) signaling pathway [42]. In
tumor cells, Akt plays a major role in resisting apoptosis
and promoting proliferation, and it does so by repro-
gramming tumor cell metabolism [43-45]. Akt sup-
presses b-oxidation of fatty acids [46], but enhances de
novo lipid synthesis in the cytosol [47,48]. Akt also acti-
vates mTOR, a key regulator of cell growth and prolif-
eration that integrates signaling from insulin and growth
factors, amino acid availability, cellular energy status
and oxygen levels [49,50]. In cancer cells, mTOR has
been shown to induce aerobic glycolysis by up-regulat-
ing key glycolytic enzymes, in particular through its
downstream effectors c-Myc and HIF-1a. Both of these
transcription factors are involved in the expression of
pyruvate kinase M2, a crucial glycolytic enzyme for
rapidly proliferating cells [51].
HIF-1a is further important for the adaption to
hypoxia by increasing the expression of glycolytic
enzymes including GLUT1 and hexokinase (HK)II as
well as several angiogenic factors [49,52]. The
observation that certain malignant cells are able to use
both glycolysis and OXPHOS under aerobic conditions
has been taken to argue that mitochondrial dysfunction
alone is not a sufficient cause for the Warburg effect
[53]. Indeed, somatic mutations in most oncogenes and
tumor suppressor genes have been shown to directly or
indirectly activate glycolysis even in the presence of oxy-
gen. As described above, they do so mainly by hyperacti-
vating major metabolic signaling pathways such as the
insulin-like growth facor-1 receptor (IGFR1)-insulin
receptor (IR)/PI3K/Akt/mTOR signaling pathway (Fig-
ure 2). In principle, hyperactivation of this pathway can
occur at several points from alterations in either
upstream (receptor) or downstream (transducer) pro-
teins and/or disruption of negative feedback loops via
loss-of-function mutations in suppressor genes
[44,45,54]. Thus, genetic alterations in oncogenes and
tumor suppressor genes are a second possible cause for
the Warburg effect.
As a third mechanism, with advanced tumorigenesis,
non-mutation induced stabilization of HIF-1a occurs
through a lack of oxygen in hypoxic tumor regions and
contributes to increased glycolysis. Proliferation of
aggressive tumors proceeds too fast for concurrent vas-
cularization, so that hypoxic regions will develop.
Because the diffusion coefficients for glucose are larger
than for oxygen, these regions rely heavily on glycolysis.
Hypoxic cancer cells are particularly radio- and che-
moresistant. In PET-studies, tumor areas with high FDG
A 
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Figure 1 PET image of a patient with a left central lung carcinoma (arrows). Note also the high FDG uptake by the kidneys (Fig D), brain
and myocard (Figure E). Source: PET/CT Imaging Centre, University Hospital of Würzburg.
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uptake have been consistently linked to poor prognosis
[55,56] and are now being considered as important bio-
logical target volumes to receive dose escalations in
radiation treatment [57].
The impact of insulin and IGF1
Finally, chronic activation of the IGFR1-IR/PI3K/Akt
survival pathway through high blood glucose, insulin
and inflammatory cytokines has been proposed as a
cause of carcinogenesis [30,58,59] and switch towards
aerobic glycolysis. In this theory, hyperactivation of the
IGFR1-IR signalling pathway does not occur primarily
through somatic gene mutations, but rather through ele-
vated concentrations of insulin and IGF1, allowing for
more ligands binding to their receptors. Interestingly,
gain-of-function mutations resulting in ligand-indepen-
dent overactivation of both IGFR1 and IR are uncom-
mon [60]. Furthermore, loss-of-function of the tumor
suppressor PTEN may result in hypersensitivity to insu-
lin/IGF1-mediated activation of the IGFR1-IR pathway
rather than constitutive downstream activation [60].
Thus, it seems possible that high levels of insulin and
IGF1 in the microenvironment favor cell survival and
evolution towards malignancy instead of apoptosis in
DNA-damaged cells. Indeed, both hyperglycemia and
hyperinsulinemia are predictors of cancer occurrence
and cancer-related mortality [23,25,26]. This highlights
the link between the metabolic syndrome and cancer on
the one hand and cancer and lifestyle factors like nutri-
tion on the other. As indicated in Figure 2, restriction of
dietary CHOs would counteract this signalling cascade
by normalizing glucose and insulin levels in subjects
with metabolic syndrome, in this way acting similar to
calorie restriction/fasting [61,62]. Indeed, it has been
shown in healthy subjects that CHO restriction induces
hormonal and metabolic adaptions very similar to fast-
ing [63-66]. Dietary restriction is able to inhibit mTOR
signalling through a second, energy-sensing pathway by
stimulating phosphorylation of AMP-activated protein
kinase (AMPK) [67]. In vitro, AMPK phosphorylation is
sensitive to the ratio of AMP/ATP within the cell; in
vivo, however, concentrations of glucose and other
nutrients are kept fairly stable throughout calorie
restriction, suggesting that hormones such as insulin
and glucagon might play a more dominant role in regu-
lating AMPK and thus mTOR activation [60]. This may
open a second route to mimic the positive effects of cal-
orie restriction through CHO restriction (Figure 2).
Glycolysis: beneficial for tumor cells
Besides the ability to grow in hypoxic environments, a
high glycolytic rate has several additional advantages for
the malignant cell: First, it avoids the production of
ROS through OXPHOS. Second, the phosphometabo-
lites that accumulate during glycolysis can be processed
in the pentose phosphate pathway for biosynthesis of
nucleic acids and lipids. Similarly, overexpession of Akt
induces an increased flow of pyruvate-derived citrate
from the mitochondrion into the cytosol, where it is
used for lipid biosynthesis. Third, a tumor cell focusing
on glycolysis no longer relies on intact mitochondria
and may evade apoptotic signalling which is linked to
mitochondrial function. In addition, the genes and path-
ways that up-regulate glycolysis are themselves anti-
apoptotic [40]. Fourth, high glycolytic activity produces
high levels of lactate and H+ ions which get transported
outside the cell where they directly promote tumor
aggressiveness [68] through invasion and metastasis, two
other hallmarks of cancer. For this purpose, glycolytic
tumor cells often show overexpression of monocarboxy-
late transporters (MCTs) and/or Na+/H+ exchangers
[69] that allow them to effectively remove large amounts
of H+ ions. For MDA-MB-231 breast cancer cells it has
been shown that lactate drives migration by acting as a
chemo-attractant and enhances the number of lung
metastasis in athymic nude mice [70]. Lactate can also
be taken up and used as a fuel by some malignant cells,
IGF1 Insulin 
blood glucose 
PI3K 
Akt 
mTOR 
AMPK 
Dietary restriction 
CHO restriction 
? IGF1R IR 
Figure 2 The IGF1R-IR/PI3K/Akt/mTOR pathway and its
manipulation through diet. Elevations in blood glucose
concentrations lead to secretion of insulin with subsequent
elevation of free IGF1. Binding of insulin and IGF1 to their receptor
tyrosine kinases induces autophosphorylation of the latter which
leads to subsequent activation of PI3K by one of at least three
different pathways [54]. Further downstream, PI3K signaling causes
phosphorylation and activation of the serine/threonine kinase Akt
(also known as protein kinase B). Akt activates mammalian target of
rapamycin (mTOR), which itself induces aerobic glycolysis by up-
regulating key glycolytic enzymes, in particular via its downstream
effectors c-Myc and hypoxia inducible factor (HIF)-1a. mTOR is
negatively affected through activation of AMPK, which can be
achieved by dietary restriction [67]. In addition, a possible negative
interaction between insulin and AMPK is discussed in vivo [60].
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and oxidative tumor cells have been shown to co-exist
with glycolytic ones (both stromal and malignant) in a
symbiotic fashion [71]. In glioma cells, lactate upregu-
lates and activates the matrix metalloproteinase (MMP)-
2 which degrades the extra-cellular matrix and basement
membrane [72]. Activation of MMPs may also occur in
the microenvironment through low pH values in a simi-
lar way as discussed for carious decay of the dentin
organic matrix through lactate released by cariogenic
bacteria [73]. Acidification of the microenvironment
further induces apoptosis in normal parenchymal and
stromal cells [74,75] and therefore provides a strong
selective growth advantage for tumor cells that are resis-
tant to low pH-induced apoptosis [76,77].
Glucose availability as a promoter of cancer
growth
Taken together, increased glucose flux and metabolism
promotes several hallmarks of cancer such as excessive
proliferation, anti-apoptotic signalling, cell cycle pro-
gression and angiogenesis. It does so, however, at the
expense of substrate inflexibility compared to normal
cells. It is clear that the high proliferative phenotype can
only be sustained as long as a steady supply of sub-
strates for ATP production is available. Thus, with pro-
gressive tumorigenesis, cancer cells become more and
more ‘addicted’ to aerobic glycolysis [53] and vulnerable
to glucose deprivation. Indeed, several studies have
shown that malignant cells in vitro quickly lose ATP
and commit apoptosis when starved of glucose [78-80].
Masur et al. showed that diabetogenic glucose concen-
trations (11 mM) compared to physiological ones (5.5
mM) lead to altered expression of genes that promote
cell proliferation, migration and adhesion in tumor cell
lines from several organs including breast, colon, pros-
tate and bladder [81]. Adding insulin to the high-glucose
medium further enhanced proliferation rates by 20-40%
and promoted activation of the PI3K pathway. The
question is whether altered blood glucose levels have
similar effects on tumor growth in vivo. Theoretically,
low blood glucose might cut some of the most hypoxic
tumor cells from their diffusion-limited fuel supply.
Gatenby and Gillies originally proposed this mechanism
as an explanation for necrotic areas often found within
tumor tissue [82], but they later revised this hypothesis
based on a mathematical model that predicted only a
modest decline of glucose concentrations with distance
from the closest blood vessel [69]. There are, however,
several lines of evidence pointing towards a strong cor-
relation between blood glucose levels and tumor growth
in vivo that might indicate other important effects
mediated by glucose. For example, the reduction of
plasma glucose levels in tumor-bearing animals induced
through calorie restriction may be responsible, directly
or indirectly, for the significantly prolonged survival
compared to normal-fed controls [83,84]. In 1962, Kor-
oljow reported the successful treatment of two patients
with metastatic tumors by an insulin-induced hypoglyce-
mic coma [85]. Hyperglycemia, on the other hand, is a
predictor of poor survival in patients with various can-
cers [22,26,86-88] and has been positively correlated to
an increased risk for developing cancer at several sites
including the pancreas, esophagus, liver, colon, rectum,
stomach and prostate in large cohort studies [25,89,90].
Indirect effects of glucose availability
Besides delivering more glucose to the tumor tissue,
hyperglycemia has two other important negative effects
for the host: First, as pointed out by Ely and Krone,
even modest blood glucose elevations as they typically
occur after a Western diet meal competitively impair
the transport of ascorbic acid into immune cells [88,91].
Ascorbic acid is needed for effective phagocytosis and
mitosis, so that the immune response to malignant cells
is diminished. Second, it has been shown in vitro and in
vivo that hyperglycemia activates monocytes and macro-
phages to produce inflammatory cytokines that play an
important role also for the progression of cancer [92-94]
(see below). Third, high plasma glucose concentrations
elevate the levels of circulating insulin and free IGF1,
two potent anti-apoptotic and growth factors for most
cancer cells [60]. Free IGF1 is elevated due to a
decreased transcription of IGF binding protein (IGFBP)-
1 in the liver mediated by insulin [95]. Due to expres-
sion of GLUT2, the b-cells of the pancreas are very sen-
sitive to blood glucose concentration and steeply
increase their insulin secretion when the latter exceeds
the normal level of ~5 mM. In the typical Western diet
consisting of three meals a day (plus the occasional
CHO-rich snacks and drinks), this implies that insulin
levels are elevated above the fasting baseline over most
of the day. Both insulin and IGF1 activate the PI3K/
Akt/mTOR/HIF-1a pathway by binding to the IGF1
receptor (IGF1R) and insulin receptor (IR), respectively
(Figure 2). In addition, insulin stimulates the release of
the pro-inflammatory cytokine interleukin (IL)-6 from
human adipocytes [96]. Thus, it could be hypothesized
that a diet which repeatedly elevates blood glucose levels
due to a high GL provides additional growth stimuli for
neoplastic cells. In this respect, Venkateswaran et al.
have shown in a xenograft model of human prostate
cancer that a diet high in CHO stimulated the expres-
sion of IRs and phosphorylation of Akt in tumor tissue
compared to a low CHO diet [97]. In colorectal [27],
prostate [24] and early stage breast cancer patients
[23,98] high insulin and low IGFBP-1 levels have been
associated with poor prognosis. These findings again
underline the importance of controlling blood sugar and
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hence insulin levels in cancer patients. Dietary restric-
tion and/or a reduced CHO intake are straightforward
strategies to achieve this goal.
Altered nutritional needs of cancer patients
Cancer patients and those with metabolic syndrome
share common pathological abnormalities. Since 1885,
when Ernst Freund described signs of hyperglycemia in
70 out of 70 cancer patients [99], it has been repeatedly
reported that glucose tolerance and insulin sensitivity
are diminished in cancer patients even before signs of
cachexia (weight loss) become evident [100-102]. Both
diabetes and cancer are characterized by a common
pathophysiological state of chronic inflammatory signal-
ling and associated insulin resistance. In cancer patients,
insulin resistance is thought to be mediated by an acute
phase response that is triggered by pro-inflammatory
cytokines such as tumor necrosis factor (TNF)-a [101]
and IL-6 [103]. In animal and human studies, removal
of the tumor resulted in improved glucose clearance,
suggesting that these cytokines are secreted, at least in
part, from the tumor tissue itself [104,105]. The impact
on the metabolism of the host is illustrated in Figure 3.
In the liver, the inflammatory process leads to increased
gluconeogenesis that is fuelled by lactate secreted from
the tumor as well as glycerol from fatty acid breakdown
and the amino acid alanine [106] from muscle proteoly-
sis. Gluconeogenesis is an energy-consuming process
and might contribute to cancer cachexia by increasing
total energy expenditure. Despite increased lipolysis,
hepatic production of ketone bodies is usually not
enhanced in cancer patients [107,108]. This is in con-
trast to starvation, where the ketone bodies acetoacetate
and b-hydroxybutyrate counteract proteolysis by provid-
ing energy for the brain and muscles [109]. In muscle,
glucose uptake and glycogen synthesis are inhibited
already at early stages of tumor progression, while fatty
acid oxidation remains at normal levels or is increased
[110,111]. In the latter case, more fat has to be provided
from lipolysis in the adipose tissue. In addition, muscles
progressively lose protein to provide amino acids for
hepatic synthesis of acute-phase proteins and as precur-
sors for gluconeogenesis. Thus, insulin resistance contri-
butes to fat loss and muscle wasting, the two hallmarks
of cancer cachexia. At the same time, it makes more
glucose in the blood available for tumor cells.
More glucose 
Substrate for gluconeogensis: 
requires energy 
Cachexia 
Lipolysis 
Lactate 
Increased fatty 
acid oxidation 
Inflammatory 
Cytokines 
Proteolysis 
Increased insulin resistance: 
 - less glucose consumption 
 - less glycogenesis 
Amino acids for gluconeogenesis and  
synthesis of acute-phase proteins 
+ + 
+ 
Inflammatory 
Cytokines 
+ 
+ 
Early stage Late stage 
Figure 3 Development of the cachectic state via sustained inflammatory signaling. Glucose metabolism in peripheral tissues is impaired
already at early stages, while hepatic gluconeogenesis increases during tumor progression at later stages.
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Fat and ketone bodies: anti-cachectic effects
It therefore seems reasonable to assume that dietary car-
bohydrates mainly fuel malignant cells which express
the insulin-independent glucose transporters GLUT1
and GLUT3, while muscle cells are more likely to bene-
fit from an increased fat and protein intake. This was
summarized as early as in 1977 by C. Young, who stated
that lipid sources predominate the fuel utilization of
peripheral tissue of patients with neoplastic disease
compared to healthy subjects [112]. In addition, most
malignant cells lack key mitochondrial enzymes neces-
sary for conversion of ketone bodies and fatty acids to
ATP [40,113,114], while myocytes retain this ability
even in the cachectic state [107]. This led some authors
to propose a high-fat, ketogenic diet (KD) as a strategy
to selectively improve body composition of the host at
the expense of the tumor [113,115,116]. The traditional
KDs, which recommended protein and CHO to account,
in combination, for roughly 20 E% (in the incorrect
assumption that they were equivalent due to gluconeo-
genesis) and fat for the remaining 80 E%, have been
widely used to treat childhood epilepsia since the 1920s
[117]. KDs are also used to treat adiposity [118] and
currently adult epilepsy [119]. In the 1980s, Tisdale and
colleagues investigated the effects of a ketogenic diet
consisting mainly of medium chain triglycerides (MCTs)
on two aggressive animal tumor models that were
known to lack the ability to utilize ketone bodies. While
the diet had no effect on rats bearing the Walker 256
sarcoma [120], it decreased the cachectic weight loss in
proportion to its fat content in mice bearing the mouse-
specific colon carcinoma MAC16 [121]. For the latter,
they further proved an anti-cachectic effect of a keto-
genic diet in which the MCTs were replaced with long
chain triglycerides (LCTs), although to a somewhat les-
ser extent [122]. Contrary to LCTs, MCTs do not
require transport in chylomicrones, but readily reach the
liver where they are metabolized to yield high amounts
of ketone bodies. Interestingly, administration of insulin
was able to reduce the weight loss similar to the keto-
genic MCT diet, but at the expense of a 50% increase in
tumor size, which could be counteracted by addition of
b-hydroxybutyrate in the drinking water [123]. The sup-
porting effect of insulin on tumor growth has been
known since 1924, when Händel and Tadenuma
described the nourishing effect of insulin on tumor tis-
sue in an animal model [124], showing evidence that
reducing insulin might reduce tumor growth.
Clinical studies on fat and cachexia
Clinical studies investigating the anti-cachectic effects of
high-fat diets are, however, rare. Fearon et al. adminis-
tered a 70% MCT diet supplemented with b-hydroxybu-
tyrate parenterally to five late-stage cachectic patients.
After seven days on the diet, mean body weight had
increased by 2 kg and their physical performance status
had improved [125]. Nebeling et al. investigated the
effects of a MCT-based ketogenic diet taken ad libitum
(60% MCT oil, 20% protein, 10% CHO, 10% other fats)
on body weight and glucose metabolism in two pediatric
patients with advanced-stage astrocytoma. Within 7 days
on the diet, blood glucose levels had decreased to nor-
mal, while glucose uptake by the tumor estimated from
FDG-PET scans had decreased by an average value of
21.8%. Notably, body weight remained stable throughout
the study period of 8 weeks. In a randomized controlled
study, Breitkreuz et al. showed that by supplementing
the normal diet of 11 under-nourished, non-diabetic
patients suffering from metastatic gastro-intestinal can-
cers with a fat-enriched liquid supplementation for 8
weeks, it was possible to reverse the loss of body weight
and lean tissue mass and to improve several quality-of-
life parameters in the treatment group, while the control
group continued to lose body and lean tissue weight
[126]. The supplement contained 66% energy from fat,
of which 45% were monounsaturated, 27% saturated
(both LCT and MCT) and 28% polyunsaturated; mean
energy intake ranged between 1000 and 2000 kcal/day
and tended to be higher in patients receiving the addi-
tional fat drink.
The benefits of mild ketosis
The study of Breitkreuz et al. shows that ketosis might
not be necessary to improve the cachectic state of can-
cer patients. In recent years, however, more evidence
has emerged from both animal and laboratory studies
indicating that cancer patients could benefit further
from a very low CHO KD. In their mouse models, Tis-
dale et al. already noted that the KD not only attenuated
the cachectic effects of the tumor, but also that the
tumors grew more slowly (although they did not attri-
bute this to a direct anti-tumor effect of b-hydroxybuty-
rate). Tumor growth inhibition through a KD has now
been established in many animal models, is supported
by a few clinical case reports, and laboratory studies
have begun to reveal the underlying molecular
mechanisms.
In vitro studies
More than 30 years ago, Magee et al. were the first to
show that treating transformed cells with various, albeit
supra-physiological, concentrations of b-hydroxybutyrate
causes a dose-dependent and reversible inhibition of cell
proliferation [116]. Their interpretation of the results
that ‘’...ketone bodies interfere with either glucose entry
or glucose metabolism... ’’ has been confirmed and
further specified by Fine et al., who connected the inhi-
bition of glycolysis in the presence of abundant ketone
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bodies to the overexpression of uncoupling protein-2
(UCP-2), a mitochondrial defect occurring in many
tumor cells [127]. In normal cells, abundant acetyl-CoA
and citrate from the breakdown of fatty acids and
ketone bodies would inhibit key enzymes of glycolysis to
ensure stable ATP levels; in tumor cells, however, the
same phenomenon would imply a decrease in ATP pro-
duction if the compensatory ATP production in the
mitochondria was impaired. For several colon and breast
cancer cell lines, Fine et al. showed that the amount of
ATP loss under treatment with acetoacetate was related
to the level of UCP-2 expression.
Very recently, Maurer et al. demonstrated that glioma
cells - although not negatively influenced by b-hydroxy-
butyrate - are not able to use this ketone body as a sub-
stitute for glucose when starved of the latter, contrary to
benign neuronal cells [128]. This supports the hypoth-
esis that under low glucose concentrations, ketone
bodies could serve benign cells as a substitute for meta-
bolic demands while offering no such benefit to malign
cells.
Animal studies
To our knowledge, the first and - with a total of 303
rats and nine experiments - most extensive study of a
KD in animals was conducted by van Ness van Alstyne
and Beebe in 1913 [129]. Experiments were divided into
two classes: in the first class, rats in the treatment arm
were fed a CHO-free diet consisting of casein and lard
for several weeks before plantation of a Buffalo sarcoma,
while the control arm received either bread only or
casein, lard and lactose. Rats on the CHO-free diet not
only gained more weight than the controls, but also
exhibited much less tumor growth and mortality rates,
the differences being “... so striking as to leave no room
for doubt that the diet was an important factor in
enabling the rats to resist the tumor after growth had
started.” In a second class of experiments using either
the slow-growing Jensen sarcoma or the aggressive Buf-
falo sarcoma, the rats were put on the CHO-free diet on
the same day that the tumor was planted. This time, dif-
ferences between the treatment and control groups were
“... so slight that ... one is left in no doubt of the ineffec-
tiveness of non-carbohydrate feeding begun at the time
of tumor implantation.” Interestingly, this parallels the
observation of Fearon et al. that rats who started to
receive a KD at the same day as tumor transplantation
did not differ from controls in either body or tumor
weight after 14 d [120]. In these rats, it was noted that
despite persistent ketosis, blood glucose levels were not
significantly lower than in controls which were also fed
ad libitum. This stability of blood glucose, independent
of ketosis, was subsequently confirmed in studies in
which mice were fed ad libitum on a KD
[84,114,121-123,130] although two studies reported a
drop in blood glucose concentrations compared with
the control group [116,131]. In the study of Magee et
al., however, diet was presented as a liquid vegetable oil
and energy intake was not monitored, allowing for the
possibility that the animals underate voluntarily, in this
way consuming a “caloric restricted KD” used in several
experimental settings from the Seyfried lab [84,114,132],
which was shown therein to be superior to the unrest-
ricted KD in tumor growth control. That “caloric
restriction” per se can hamper tumor growth has been
impressively demonstrated already in 1942 by A. Tan-
nenbaum in a series of comprehensive mouse models
with different mouse strains and tumor induction types
[133]. Throughout all experimental series, a strict
restriction of food intake (impeding weight gain) several
weeks before inducing tumorigenesis by application of
3,4 benzpyrene decreased the appearance rate and
appearance time of tumors in the diet mice compared
to the ad libitum controls. Notably, the calorie-
restricted diet was composed of 53% CHOs compared
to 69% in the control group. Despite a lack of data on
blood glucose and ketone body levels, it could be specu-
lated that the strict restriction of food per se (to 50-60%
of the control group) induced a ketotic state and thus
the ketones were - at least to some extend - responsible
for the effects observed.
In Table 1, we summarize the main results of various
mouse studies that determined the effects of KDs on
tumor growth and host survival. The results seem to
indicate an anti-tumor effect of ketosis. Freedland et al.
indeed reported that the mice with the highest levels of
ketone bodies had the longest survival times in a human
prostate cancer xenograft model [134]. But other studies
suggest that there are further possible factors to con-
sider. Seyfried et al. used linear regression to show that
plasma glucose and IGF1 levels are a better predictor of
tumor growth than ketone bodies in a murine astrocy-
toma model [84]. Tumor growth in this as well as in a
follow-up [114] study was only retarded when the KD
had been restricted to induce body weight loss, again
underlining the effect of caloric restriction per se. This
contrasts with other studies showing growth-inhibitory
effects of unrestricted or higher-caloric KDs despite
neither decreases in blood glucose concentration nor
body weight loss compared with a control group
[130,134,135]. According to Otto et al., whose diet had
been enriched in MCT and omega-3 fatty acids, fat
quality might play a role in explaining these results
[130]. The situation in humans might be different as
well, as for example Fine et al. found no correlation
between calorie intake or weight loss and disease pro-
gression in ten patients on an unrestricted KD [136]
(see also below).
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Table 1 Animal studies that have investigated the effects of a KD on tumor progression and host survival
animals n tumor feeding C/P/F major fat
source
diet
initiation
diet
duration
BW vs.
controls
BG vs.
controls
other effects vs. controls Ref.
(E%) (d) (d)
C57BL/6
mice
18 B16
melanoma
ad libitum 0/0/
100 1
PUFA
vegetable oil
0 14 - ↓ b lower number of lung
metastases b
[116]
BALB/c
mice
20 Medina-
Oborn-
Danielson
mammary
tumor
restricted
to 60 E%
of control
30/60/
5
hydrogenated
vegetable oil
~ 14 70 ↓ ↓ c mortality rate ↓ c [83]
NMR1
mice
>
15
MAC16
colon
carcinoma
ad libitum .../.../80
2
MCT emulsion 8 20 ↑ - 50% less weight loss b; left35%
less tumor weight
[121]
NMR1
mice
... MAC16
colon
carcinoma
ad libitum .../.../80 14 - 21 9 ↑ - 36% less weight loss a [123]
32% less tumor weight c
less nitrogen output a
C57BL/6
mice
6 CT-2A
mouse
astrocytoma
restricted
to 60 E%
of control
0/8/92 lard 1 13 ↓ 3 ↓ 3 80% less tumor weightb;
plasma IGF1 levels ↓ b,3
[84]
C57BL/6
mice
11 CT-2A
mouse
astrocytoma
ad libitum 3/17/
80
soy oil
(KetoCal©)
3 > 8 - - no significant differences in
either tumor weight, survival
or vascularity
[114]
+ + +
BALB/cJ
SCID
mice
14 U87
glioblastoma
restricted
to 65-70
E% of
control
3/17/
80
soy oil
(KetoCal©)
3 >8 ↓ b ↓ b 65% (CT-2A)band 35% (U87)
cless tumor wet weight;
longer survival b; lower
number of blood vessels (both
tumors)
nu/nu
mice
20 LNCaP
human
prostate
cancer
ad libitum 10/45/
45
... 14 63 ↓ a ... plasma insulin levels ↓ c;
plasma IGF1 levels ↓ c;
[97]
45% less tumor volume a;
43% less tumor dry weightc;
decreased levels of
phosphorylated Akt (below
detected limits) and insulin
receptor in tumor tissue
SCID
mice
25 LAPC-4
human
prostate
cancer
9% more
energy
than
control
0/16/
84
milk fat + lard -24 > 40 - ↑ c longer survival b [134]
NMRI
mice
12 23132/87
human
gastric
adenoma
ad libitum 0/14/
86
cheese + MCT
+ omega-3 oil
0 > 16 - - longer survival a; [130]
tumor growth rate ↓ c;
larger necrotic area in tumors
b
C3H/HeN
mice 4
5 squamous
cell car-
cinoma VII
ad libitum 16/58/
26
... -7 16 ↑ ↓ 41% less tumor volume d [131]
Foxn1nu
mice
12 LNT-229
glioma cells
ad libitum 0/13/
36
flaxseed and
hempseed oil
1 > 63 - - no significant differences in
survival, tumor growth and
plasma IGF1 levels
[128]
In all but one cases, control diets contained a minimum of 40% CHO. Diet initiation refers to the time of tumor cell plantation.
SCID = Severe Combined Immunodeficiency; C/P/F = ratio of CHO:protein:fat; E% = percent of energy; BW = body weight; BG = blood glucose
1 plus not further specified pellets on days 5, 8 and 11/2 plus 3 mg/ml beta-hydroxybutyrate in drinking water/3 controls were fed a KD ad libitum, not high-CHO/
4 similar results for Rag2M mice bearing human colorectal HCT-116 tumors/a p < 0.005; b p < 0.01; c p < 0.05; d p < 0.1
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Concerning fat quality, Freedland et al. observed that a
diet rich in corn oil might stimulate prostate cancer
growth to a greater extent than one rich in saturated fat
[134]. A recent study suggests, however, that tumor
growth inhibition neither depends on fat quality nor
ketone body levels [131]. In this case, mice injected with
either murine squamous cell carcinoma or human color-
ectal carcinoma cells received a low CHO, high-protein
diet in which ~ 60 E% was derived from protein, 10-15
E% from CHO and ~ 25 E% from fat. No systemic keto-
sis was measured, yet tumors grew significantly less
compared with a standard diet containing 55 E% from
CHO and 22 E% from the same fat source. IGF1 levels
and body weight remained stable, so these findings
could not be attributed to one of these factors. There
was, however, a significant drop in blood glucose, insu-
lin and lactate levels, and a positive correlation between
blood lactate as well as insulin levels and tumor growth
was found. The study of Venkateskwaran et al. indicates
that in prostate cancer insulin and/or IGF1 play major
roles in driving tumor cell proliferation [97].
The diversity of these findings should not be surpris-
ing, given the variety of mice strains, tumor cell lines,
diet composition and time of diet initiation relative to
tumor planting. Instead, it seems remarkable that the
same basic treatment, namely drastic restriction of
CHOs, apparently induces anti-tumoral effects via differ-
ent pathways. Thus, it may depend on the circumstances
which variables - including blood glucose, insulin, lac-
tate, IGF1, fat quality and ketone bodies - are the best
predictors of and responsible for the anti-tumor effects
of very low CHO diets.
Human studies
Until now, no randomized controlled trials have been
conducted to evaluate the effects of a KD on tumor
growth and patient survival. It has to be noted in gen-
eral, however, that any dietary intervention requiring a
dramatic change of life style makes randomized studies
nearly impossible - however, even prospective cohort
studies are missing. There is only anecdotal evidence
that such a diet might be effective as a supportive treat-
ment. One study investigated whether a high-fat diet
(80% non-nitrogenous calories from fat) would inhibit
tumor cell replication compared to a high-dextrose diet
(100% non-nitrogenous calories from dextrose) in 27
patients with gastro-intestinal cancers [137]. Diets were
administered parenterally and cell proliferation assessed
using thymidine labeling index on tumor samples. After
14 days, the authors found a non-significant trend for
impaired proliferation in the high-fat group. Whether
ketosis was achieved with this regime was not evaluated,
but blood glucose levels were comparable in both trial
groups. A very recent pilot trial demonstrated the
feasibility of a low CHO up to a ketogenic regimen
implemented for 12 weeks in very advanced outpatient
cancer patients. Notably, severe side effects were not
observed, nearly all standard blood parameters improved
and some measures of quality of life changed for the
better [138]. The first attempt to treat cancer patients
with a long-term controlled KD was reported by L.
Nebeling in 1995 for two pediatric patients with astrocy-
toma [139]. The results of those two cases were very
encouraging and the diet was described in detail in
another publication [140]. Implementing a KD with
additional calorie restriction in a female patient with
glioblastoma multiforme clearly demonstrated that this
intervention was able to stop tumor growth [132]. This
was achieved, however, on the expense of a dramatic
weigh loss of 20% over the intervention period, which is
no option for the majority of metastatic cancer patients
being in a catabolic state. A first clinical study applying
a non-restricted KD for patients with glioblastoma
(ERGO-study, NHI registration number NCT00575146),
which was presented at the 2010 ASCO meeting [141],
showed good feasibility and suggested some anti-tumor
activity. The protocol of another clinical interventional
trial (RECHARGE trial, NCT00444054) treating patients
with metastatic cancer by a very low CHO diet was pub-
lished in 2008 [142], and preliminary data from this
study presented at the 2011 ASCO-meeting showed a
clear correlation between disease stability or partial
remission and high ketosis, independent of weight loss
and unconscious caloric restriction of the patients [136].
While a randomized study for the treatment of prostate
cancer patents applying the Atkins diet (NCT00932672)
is currently recruiting patients at the Duke University,
another trial posted at the clinical trials database (Clini-
calTrials.gov) is not yet open for recruitment
(NCT01092247). Very recently, two Phase I studies
applying a ketogenic diet based on KetoCal® 4:1 started
recruitment at the University of Iowa, intended to treat
prostate cancer patients (KETOPAN, NCT01419483)
and non-small cell lung cancer (KETOLUNG,
NCT01419587). Thus, in the future, several data should
be available to judge whether this kind of nutrition is
useful as either a supportive or even therapeutic treat-
ment option for cancer patients.
Is there a role for carbohydrate restriction in the
prevention of cancer?
“Prevention of cancer” can refer to either the inhibition
of carcinogenesis per se or - once that cells made the
transition to malignancy - the sufficient delay of tumor
growth, so that it remains undetected and asymptomatic
during a subject’s lifespan. There is evidence that even
modest CHO restriction may influence both of these
mechanisms positively through various pathways. The
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IGF1R-IR pathway has already been discussed: once a
potentially carcinogenic somatic mutation has occurred,
the probability for carcinogenesis of a cell that is bor-
derline between apoptosis and malignancy might be
raised by high levels of insulin and IGF1 in the micro-
environment. Once a cell became malignant, high insu-
lin and IGF1 levels might accelerate proliferation and
progression towards a more aggressive, glycolytic pheno-
type. In rats treated with the carcinogen N-methyl-N-
nitrosourea, it has been shown that lowering the CHO
content of the diet from 60 E% to 40 E% with a simulta-
neous increase in protein was sufficient to lower post-
prandial insulin levels as well as decrease the
appearance rate of tumors from (18.2 ± 1.3)%/wk to
(12.9 ± 1.4)%/wk (p < 0.05), however with no statistically
significant effect on tumor latency and weight measured
after 10 wk [143]. Similarly, a recent study reported that
NOP mice, which normally have a 70 - 80% chance of
developing breast cancer over their lifetime due to
genetic mutations, stayed tumor-free at 1 year of age
when their calories from CHO were limited to 15%,
while almost half of those on a 55% CHO diet devel-
oped tumors [131]. Notably, only 3 out of 11 mice in
the 15% CHO group died with having a tumor com-
pared to 7 out of 10 in the 55% CHO group; at death,
significantly lower plasma insulin levels had been mea-
sured for the low CHO group. These results support the
epidemiological [25,29,31,32] and in vitro [81,144] find-
ings that high CHO diets, in particular those including
high GI foods, promote mammary tumorigenesis via the
sustained action of insulin.
Lower insulin levels may further increase the chance
of intermittent ketosis, in particular if CHO restriction
is combined with exercise, calorie restriction or inter-
mittent fasting. Seyfried and Shelton [40] pointed out
the possibility of ketone bodies to help in cancer pre-
vention through their ability to protect the mitochondria
from inflammation and ROS. Being more satiating than
low-fat diets [145,146], a low CHO diet would make it
easier to avoid caloric overconsumption or to implement
intermittent fasting as an additional lifestyle change
[147].
Avoidance of chronic inflammation
Another potential benefit of low CHO diets might lie in
their influence upon inflammatory processes that take
place within various tissues. Inflammation is a well-
established driver of early tumorigenesis and accompa-
nies most, if not all cancers [148]. Chronic, ‘smoulder-
ing’ inflammation can both cause and develop along
with neoplasia. There is evidence that chronic intake of
easily digestible CHOs is able to promote such an
inflammatory state in leukocytes and endothelial cells
[94]. In obese individuals [149] and healthy subjects
who underwent eccentric exercise training [150], the
inflammatory state was further augmented postpran-
dially through a high CHO intake, but not through
high-fat, low CHO meals in the latter study. Maybe
more importantly, even moderate CHO restriction has
been shown to effectively target several important mar-
kers of atherosclerosis and type II diabetes, both of
which are associated with chronic inflammation
[151-157]. Forsythe et al. showed that in overweight
individuals with dyslipidemia a very low CHO diet had a
more favorable effect than a low fat diet in reducing sev-
eral markers of inflammation [158]. Given these find-
ings, it can be hypothesized that a diet with a low GL
positively affects cancer risk through reducing postpran-
dial hyperglycemia and the associated inflammatory
response.
In this context, it is important to note that a low
CHO diet offers further possibilities to target inflamma-
tion through omission or inclusion of certain foods.
Usually, CHO restriction is not only limited to avoiding
sugar and other high-GI foods, but also to a reduced
intake of grains. Grains can induce inflammation in sus-
ceptible individuals due to their content of omega-6
fatty acids, lectins and gluten [159,160]. In particular
gluten might play a key role in the pathogenesis of
auto-immune and inflammatory disorders and some
malignant diseases. In the small intestine, gluten triggers
the release of zonulin, a protein that regulates the tight
junctions between epithelial cells and therefore intest-
inal, but also blood-brain barrier function. Recent evi-
dence suggests that overstimulation of zonulin in
susceptible individuals could dysregulate intercellular
communication promoting tumorigenesis at specific
organ sites [161].
Paleolithic-type diets, that by definition exclude grain
products, have been shown to improve glycemic control
and cardiovascular risk factors more effectively than
typically recommended low-fat diets rich in whole grains
[162]. These diets are not necessarily very low CHO
diets, but focus on replacing high-GI modern foods with
fruits and vegetables, in this way reducing the total GL.
This brings us back to our initial perception of cancer
as a disease of civilization that has been rare among
hunter-gatherer societies until they adopted the Western
lifestyle. Although there are certainly many factors con-
tributing to this phenomenon, the evidence presented in
this review suggests that reduction of the high CHO
intake that accounts for typically > 50 E% in the Wes-
tern diet may play its own important role in cancer pre-
vention and outcome.
Conclusions
We summarize our main findings from the literature
regarding the role of dietary CHO restriction in cancer
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development and outcome.
(i) Most, if not all, tumor cells have a high demand
on glucose compared to benign cells of the same tis-
sue and conduct glycolysis even in the presence of
oxygen (the Warburg effect). In addition, many can-
cer cells express insulin receptors (IRs) and show
hyperactivation of the IGF1R-IR pathway. Evidence
exists that chronically elevated blood glucose, insulin
and IGF1 levels facilitate tumorigenesis and worsen
the outcome in cancer patients.
(ii) The involvement of the glucose-insulin axis may
also explain the association of the metabolic syn-
drome with an increased risk for several cancers.
CHO restriction has already been shown to exert
favorable effects in patients with the metabolic syn-
drome. Epidemiological and anthropological studies
indicate that restricting dietary CHOs could be ben-
eficial in decreasing cancer risk.
(iii) Many cancer patients, in particular those with
advanced stages of the disease, exhibit altered
whole-body metabolism marked by increased plasma
levels of inflammatory molecules, impaired glycogen
synthesis, increased proteolysis and increased fat uti-
lization in muscle tissue, increased lipolysis in adi-
pose tissue and increased gluconeogenesis by the
liver. High fat, low CHO diets aim at accounting for
these metabolic alterations. Studies conducted so far
have shown that such diets are safe and likely bene-
ficial, in particular for advanced stage cancer
patients.
(iv) CHO restriction mimics the metabolic state of
calorie restriction or - in the case of KDs - fasting.
The beneficial effects of calorie restriction and fast-
ing on cancer risk and progression are well estab-
lished. CHO restriction thus opens the possibility to
target the same underlying mechanisms without the
side-effects of hunger and weight loss.
(v) Some laboratory studies indicate a direct anti-
tumor potential of ketone bodies. During the past
years, a multitude of mouse studies indeed proved
anti-tumor effects of KDs for various tumor types,
and a few case reports and pre-clinical studies
obtained promising results in cancer patients as well.
Several registered clinical trials are going to investi-
gate the case for a KD as a supportive therapeutic
option in oncology.
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